Install
Cancellations, Closures & Delays Meet Our Marketing Gurus Green Gold Fan Zone Never Forgotten Honor Flight Grand Theater 2025-26 Season ↪ How to Listen: Apps & Smart Speakers!
- 4,238articles · 30d
- 3+ hour agolatest article
- Aug 15, 2026earliest in window
- 15%with images
- 271avg words
- business 1,489
- world 1,230
- world news 1,120
- sports 955
- politics 947
- (midwest communications 703
- donald trump 649
- markets 613
- mc complete - state & national 599
- conservative talk 597
- brian kilmeade 552
- clay travis 508
- buck sexton 471
- sean hannity 441
- technology 434
- economy 413
- mark levin 404
- finance 389
- joe pags 364
- ap sports news 338
- News 1,390
- Economy, Business & Finance 1,334
- Politics 1,053
- Finance & Business 1,051
- Sports & Fitness 934
- Sports 929
- Sport 852
- Sensitive Subjects 671
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
US FDA approves Scholar Rock’s muscle weakness drug
2+ day, 14+ hour ago (80+ words) Sept 11 (Reuters) - The U.S. Food and Drug Administration on Friday approved Scholar Rock's therapy to treat a rare genetic condition that causes muscle weakness. (Reporting by Sneha S K in Bengaluru; Editing by Tasim Zahid)... US FDA approves Scholar…...
Astrazeneca’s breast cancer drug fails late-stage trial
2+ day, 14+ hour ago (77+ words) Sept 11 (Reuters) - AstraZeneca said on Friday its breast cancer drug failed to meet the main goal of improving progression-free survival during a late-stage trial. (Reporting by Christy Santhosh in Bengaluru; Editing by Tasim Zah... Astrazeneca’s breast cancer drug fails late-stage…...
US FDA pauses new enrollment in Biohaven’s epilepsy drug trials
4+ day, 19+ min ago (278+ words) Sept 10 (Reuters) – Biohaven said on Thursday the U.S. FDA had imposed a partial clinical hold, pausing new patient enrollment in trials of its experimental epilepsy drug after rodent findings, sending its shares down more than 13% in premarket trading. Here are…...
Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers
5+ day, 18+ hour ago (317+ words) Sept 8 (Reuters) – Shares of Dyne Therapeutics and Sarepta slumped on Tuesday after Novartis’ treatment for a muscle-wasting disorder failed in a trial, fueling investor concerns about the prospects of similar therapies for the tough-to-treat rare disease. Dyne’s stock led declines…...
Pharvaris’ genetic disorder drug meets main goal in late-stage trial
6+ day, 5+ min ago (249+ words) Sept 8 (Reuters) – Pharvaris said on Tuesday its experimental oral drug helped prevent swelling attacks in patients with hereditary angioedema, meeting the main goal of a late-stage trial. Shares of the company were up over 25% in premarket trading. • Hereditary angioedema causes…...
Bristol Myers’ blood cancer cell therapy succeeds in mid-stage trial
6+ day, 5+ min ago (257+ words) Sept 8 (Reuters) – Bristol Myers Squibb said on Tuesday its experimental cell therapy showed a high overall response rate in a mid-stage trial, in patients with a hard-to-treat form of blood cancer. The study evaluated the therapy, called arlocabtagene autoleucel, or…...
Novartis announces trial setback on del-desiran drug
6+ day, 5+ hour ago (176+ words) ZURICH, Sept 8 (Reuters) – Swiss drugmaker Novartis on Tuesday said a late-stage study assessing drug del-desiran’s impact on myotonic dystrophy, a form of muscle wasting, had not met its target on a key metric, but reaffirmed its sales guidance through 2030. Novartis…...
Novo scraps two more heart drug trials, further dimming growth beyond obesity
1+ week, 12+ min ago (191+ words) Sept 7 (Reuters) – Novo Nordisk said on Monday it had halted two additional trials of its experimental cardiovascular drug ziltivekimab, further denting the Danish drugmaker’s efforts to diversify beyond its blockbuster obesity and diabetes franchise. In July, Novo said ziltivekimab failed…...
Ionis, Novartis’ key experimental heart drug fails in late-stage trial
1+ week, 2+ day ago (160+ words) Sept 4 (Reuters) – Ionis Pharmaceuticals and partner Novartis’ experimental drug to lower high levels of a cholesterol-carrying particle in heart patients failed in a late-stage trial, the companies said on Friday. Shares of Ionis fell 6% in aftermarket trading. The drug, pelacarsen,…...
Cyclosporiasis outbreak exposes a weakened US public health system
1+ week, 3+ day ago (907+ words) YPSILANTI, Michigan, Sept 4 (Reuters) – During the height of the summer outbreak of cyclosporiasis, Dea Lancaster set aside her usual duties as nurse coordinator at Michigan’s Washtenaw County Health Department to call patients, asking about their symptoms and tracing the contaminated…...